Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience

To date, adalimumab (ADA) is the only biotechnology drug approved for the management of hidradenitis suppurativa (HS), an inflammatory skin condition. However, it quickly became apparent that the efficacy of adalimumab in daily practice was highly variable. In our review, we highlighted the current...

Descripción completa

Detalles Bibliográficos
Autores principales: Martora, Fabrizio, Megna, Matteo, Battista, Teresa, Potestio, Luca, Annunziata, Maria Carmela, Marasca, Claudio, Villani, Alessia, Fabbrocini, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869696/
https://www.ncbi.nlm.nih.gov/pubmed/36698446
http://dx.doi.org/10.2147/CCID.S391356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869696/
https://www.ncbi.nlm.nih.gov/pubmed/36698446
http://dx.doi.org/10.2147/CCID.S391356

Ejemplares similares